Hollywood R&D Tax Credit Benefits for Businesses

R&D Tax Credits for Hollywood, Florida Businesses

Hollywood, Florida, thrives in industries such as healthcare, tourism, education, and retail. Top companies in the city include Memorial Healthcare System, a major healthcare provider; Seminole Hard Rock Hotel & Casino, a prominent tourism and hospitality company; Broward College, a key educational institution; Walmart, a global retail giant; and Amazon, a global logistics and e-commerce company. The R&D Tax Credit can benefit these industries by reducing tax liabilities, fostering innovation, and improving business performance. By leveraging the R&D Tax Credit, companies can reinvest savings into advanced research boosting Hollywood’s economic growth.

Find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 13727 SW 152 Street, Miami is less than 20 miles from Hollywood and provides R&D tax credit consulting and advisory services to Hollywood and the surrounding areas such as: Miami, Fort Lauderdale, Pompano Beach, Miramar and Davie.

If you have any questions or need further assistance, please call or email our local Miami Partner on (786) 404-1316.
Feel free to book a quick teleconference with one of our Florida R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Hollywood, Florida Patent of the Year – 2024/2025

Somerset Therapeutics LLC has been awarded the 2024/2025 Patent of the Year for its innovative ophthalmic formulation. Their invention, detailed in U.S. Patent No. 11857538, titled ‘Stable pilocarpine formulations with modified buffer characteristics and related methods’, utilizes a reduced-buffer pilocarpine composition to enhance stability and patient comfort in treating presbyopia and related eye conditions.

The patented formulation features a lower buffer content and capacity compared to existing products. This adjustment maintains the solution’s stability while minimizing potential ocular irritation. By carefully balancing the concentration of pilocarpine with a uniquely characterized buffer component, the composition achieves therapeutic efficacy with improved tolerability.
Traditional pilocarpine eye drops often use higher buffer concentrations, which can lead to discomfort upon application. Somerset’s approach addresses this issue by reducing buffer strength without compromising the drug’s effectiveness. This innovation is particularly beneficial for patients requiring long-term treatment, as it may enhance adherence by reducing side effects.

The development of this formulation reflects Somerset Therapeutics’ commitment to improving ophthalmic therapies. By focusing on patient-centric solutions, the company continues to advance treatments that align with both clinical efficacy and user comfort.